HRAS and neoplasm: Tipifarnib also increased tumor growth inhibition with palbociclib in the majority of HRAShigh models tested, but cetuximab was highly active in all four PDX studied, precluding assessment of this combination in these models; previous work suggests that HRAS signaling is a key driver of cetuximab resistance in experimental models and in the clinic [61].